Astellas FY17 Results and FY18e Guidance – No Major Surprise
Astellas Pharma Inc (4503 JP) FY17 results Xtandi (up 17% to ¥295b) and mirabegron (up 28% to ¥126b) ramp-up compensate for lackluster domestic...
120 Views
Will Actinogen Ace Alzheimer's?
Alzheimer’s disease is an incurable neurodegenerative disorder that robs the affected individuals of memory, self-care and quality of life,...
229 Views
Will Alibaba Prevent an All-Out Food Crisis in China?
We believe there is scope for a food crisis in China. In this note, we take a deep look at the dynamics of food consumption in China and note four...
197 Views
AK Medical: Take It If The Answers Are Good
AK Medical Holdings (1789 HK) is a new listing with a proposed price range of HKD1.66 -2.00. The company is China's leading (in volume) orthopedic...
637 Views
Machine Trades with a Hammer and Taking the Other Side (Trading the Vol Beneath the Surface)
The recent sell-off and bounce back of Target Corp (TGT US) (Beta of 0.4 – 0.6!!) last week tells a story of volatility not told by the VIX Index...
195 Views